← All organizations
Highest phase reached
Phase 3
First clinical trial
Jan 1, 2002First marketed drug
Jan 1, 2002First NDA
Mar 7, 2008Last known activity
May 12, 2022
Acquired by Repligen Corporation on Jun 27, 2017
Timeline
2000s
- Jan 1, 2002
Spectrum Pharmaceuticals— Founded
- Mar 7, 2008
levoleucovorin— NDA Organization
2010s
- Sep 6, 2012
Allos Therapeutics— Acquired
- Jan 1, 2013
Talon Therapeutics— Acquired
- Mar 10, 2016
melphalan— NDA Secondary Org
- Jun 27, 2017
Repligen Corporation— Acquired By
- May 9, 2019
ImmunGene Inc.— Acquired
2020s
- Sep 9, 2022
eflapegrastim— Marketing Organization
Drugs by trial phase (75 distinct, 103 trials)
Phase 3 (20 own, 0 via acquisition)
Phase 2 (41 own, 1 via acquisition)
Indications
Studied for
- Acute Disease
- Adenocarcinoma
- Amyloidosis
- Attention Deficit Disorder with Hyperactivity
- Biliary Tract Neoplasms
- Brain Neoplasms
- Breast Neoplasms
- Carcinoma
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Ovarian Epithelial
- Carcinoma, Transitional Cell
- Esophageal Neoplasms
- Esophageal Squamous Cell Carcinoma
- Exanthema
- Glioblastoma
- Hodgkin Disease
- Hyperkinesis
- Hyperplasia
- Hypertrophy
- Immunoblastic Lymphadenopathy
- Immunoglobulin Light-chain Amyloidosis
- Leukemia
- Leukemia, B-Cell
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Lymphoid
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Leukemia, T-Cell
- Lower Urinary Tract Symptoms
- Lung Neoplasms
- Lymphoma
- Lymphoma, B-Cell
- Lymphoma, B-Cell, Marginal Zone
- Lymphoma, Follicular
- Lymphoma, Large B-Cell, Diffuse
- Lymphoma, Large-Cell, Anaplastic
- Lymphoma, Mantle-Cell
- Lymphoma, Non-Hodgkin
- Lymphoma, Primary Cutaneous Anaplastic Large Cell
- Lymphoma, T-Cell
- Lymphoma, T-Cell, Cutaneous
- Lymphoma, T-Cell, Peripheral
- Melanoma
- Mucositis
- Multiple Myeloma
- Mycoses
- Mycosis Fungoides
- Neoplasm Metastasis
- Neoplasms
- Neoplasms, Plasma Cell
- Neoplasms, Second Primary
- Neoplasms, Unknown Primary
- Nervous System Diseases
- Neuroblastoma
- Neutropenia
- Ovarian Neoplasms
- Peripheral Nervous System Diseases
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
- Prostatic Hyperplasia
- Prostatic Neoplasms
- Renal Insufficiency
- Sarcoma
- Sezary Syndrome
- Small Cell Lung Carcinoma
- Urinary Bladder Neoplasms
- Uveal Neoplasms
- Waldenstrom Macroglobulinemia
- Wilms Tumor
Marketed drugs (6)
Subsidiaries (3 direct, 3 total across the full acquisition tree)
Recent trials (50)
- NCT05378763Lead sponsorPhase 3May 12, 2022
- NCT04981704Lead sponsorPhase 1Apr 8, 2021
- NCT04981704Study directorPhase 1Apr 8, 2021
- NCT04570423Lead sponsorPhase 2Sep 30, 2020
- NCT04402008Lead sponsorPhase 1/Phase 2Jun 30, 2020
- NCT04402008Study directorPhase 1/Phase 2Jun 30, 2020
- NCT04436562Study directorPhase 1May 29, 2020
- NCT04436562Lead sponsorPhase 1May 29, 2020
- NCT04172597Lead sponsorPhase 2Dec 31, 2019
- NCT04187898Lead sponsorPhase 1Dec 16, 2019
- NCT03804515Lead sponsorPhase 1Mar 31, 2019
- NCT03417284CollaboratorPhase 1/Phase 2Nov 30, 2018
- NCT03744715Lead sponsorPhase 2Oct 5, 2018
- NCT03429101Lead sponsorPhase 1May 31, 2018
- NCT03318939Lead sponsorPhase 2Oct 13, 2017
Details
- Founded
- Henderson, NV, US Jan 1, 2002
- First NDA
- Mar 7, 2008
- Last known activity
- May 12, 2022
Designations held
- Orphan drug
- Fast track
- Priority review
- Accelerated approval